I am a board-certified medical physicist specializing in brachytherapy. My clinical activities include leading the brachytherapy physics team in our mission of designing and delivering brachytherapy treatments and ensuring the quality of our clinical operations. I contribute to the development of new methods and techniques to further the scope of brachytherapy and oversee the implementation of new technologies. I also participate in patient safety efforts outside of brachytherapy within the departments of Medical Physics and Radiation Oncology.
My research has focused on the use of technological innovation to enhance quality assurance efficacy and efficiency, and the use of process analysis to improve the safety of the brachytherapy practice. Other areas of clinical and research focus have been image-guided brachytherapy using MR and CT and development of novel brachytherapy applicators and techniques.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Antonio Damato discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures